Ultragenyx Pharmaceutical 2024年第四季度GAAP每股亏损$(1.39)逊于预期$(1.29)，销售额$164.877M逊于预估$155.393M

财报速递2025-02-14
Ultragenyx Pharmaceutical（NASDAQ:RARE）公布季度每股亏损 $(1.39)，逊于分析师一致预期的 $(1.29)，相差7.75%。与去年同期的每股亏损 $(1.52) 相比，这一亏损上升了8.55%。公司报告的季度销售额为 $164.877M，逊于分析师一致预期的 $155.393M，相差100.00%。与去年同期的 $127.392M 相比，这一销售额下降了100.00%。

以上内容来自Benzinga Earnings专栏，原文如下：

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.29) by 7.75 percent. This is a 8.55 percent increase over losses of $(1.52) per share from the same period last year. The company reported quarterly sales of $164.877 which missed the analyst consensus estimate of $155.393 million by 100.00 percent. This is a 100.00 percent decrease over sales of $127.392 million the same period last year.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法